China SXT Pharmaceuticals Inc.

SXTC | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.93

-$0.05 (-1.68%)

At close: Nov 5, 2026, 4:00 PM ET

$2.90

-$0.03 (-1.02%)

After-hours: Nov 5, 2026, 7:28 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $15.65K

Enterprise Value $-27.04M

Beta 2.02

Average Volume 14.38M

Shares Outstanding (Diluted) 5.86K

Shares Change YoY -76.02%

Institutional Ownership 0.00%

Exchange NASDAQ

ISIN VGG2161P1817

Price Performance

Price Change 1M -97.7%

Price Change 3M -32.0%

Price Change 6M -97.8%

Price Change YTD -100.0%

Price Change 1Y -100.0%

Price Change 3Y -100.0%

Price Change 5Y -100.0%

1M CAGR (ann.) -98.8%

1Y CAGR (ann.) -100.0%

5Y CAGR (ann.) -98.6%

All-Time CAGR -95.6%

Valuation

PE Ratio -0.00

Forward PE N/A

PEG Ratio 0.00

Forward PEG 0.00

PS Ratio 0.01

Forward PS N/A

PB Ratio 0.00

P/FCF Ratio -0.00

P/Adj. FCF Ratio -0.00

P/OCF Ratio -0.00

EV/Sales -25.21

EV/EBIT 3.80

EV/EBITDA 3.87

EV/FCF 4.49

Earnings Yield -26677.8%

FCF Yield -37869.6%

Adj. FCF Yield -54540.7%

Financial Health

Net Cash $27.11M

Total Debt $1.12M

Cash & Short-Term Investments $28.18M

Total Assets $34.75M

Current Ratio 7.93

Quick Ratio 7.25

Debt / Equity Ratio 0.04

Debt / EBITDA -0.16

Debt / FCF -0.19

OCF / Debt -5.38

Interest Coverage -169.69

Altman Z-Score -0.98

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 17.1%

Operating Profit Margin -996.1%

EBITDA Margin -650.7%

Net Profit Margin -578.5%

FCF Margin -561.8%

Adj. FCF Margin -809.1%

SBC / Revenue 247.3%

SBC Impact (per share) -44.0%

Returns

Return on Assets -17.9%

Return on Equity -24.9%

Return on Invested Capital -26.8%

Return on Capital Employed -35.1%

Return on Tangible Assets -17.9%

Historical Growth (CAGR)

Revenue CAGR 3Y -29.1%

Revenue CAGR 5Y -35.3%

Revenue CAGR 10Y -11.7%

EPS CAGR 3Y 31.0%

EPS CAGR 5Y 77.0%

EPS CAGR 10Y -0.9%

FCF CAGR 3Y -64.3%

FCF CAGR 5Y -36.0%

FCF CAGR 10Y -38.3%

Analyst Forecasts

Analyst Rating Hold

Analyst Count 0

EPS Growth Next 3Y N/A

Revenue Growth Next 3Y N/A

Earnings Date Oct 7, 2026

EPS Estimate (next Q) N/A

EPS Growth Est (next Q) N/A

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $0.00

Price Target Upside N/A

Cash Flow

Operating Cash Flow $-6.03M

Free Cash Flow $-6.03M

Adj. Free Cash Flow $-8.68M

FCF Per Share -$1,028.71

OCF Per Share -$1,028.71

OCF/S Ratio -561.8%

Income Statement

Revenue $1.07M

Gross Profit $183.28K

Operating Income $-10.68M

EBITDA $-6.98M

Net Income $-6.21M

EPS (Diluted) -$795.00

Revenue / Employee $19.15K

Profit / Employee $-110.81K

Employees 56